Alvimopan: A cost-effective tool to decrease cystectomy length of stay

Jules Powers Manger, Marc Nelson, Shawnna Blanchard, Sevann Helo, Mark Conaway, Tracey L Krupski, Jules Powers Manger, Marc Nelson, Shawnna Blanchard, Sevann Helo, Mark Conaway, Tracey L Krupski

Abstract

Introduction: We sought to evaluate the cost effectiveness of perioperative use of alvimopan in cystectomy and urinary diversion. A recent randomized controlled trial demonstrated the efficacy of alvimopan in reducing postoperative ileus and length of stay in cystectomy; however, a major limitation was the exclusion of epidural analgesia.

Materials and methods: Eighty-six cystectomy and urinary diversion procedures performed by seven surgeons were analyzed between January 2008 and April 2012. The first 50 patients did not receive alvimopan perioperatively, while the subsequent 36 received a single dose of 12 mg preoperatively and then 12 mg every 12 hours for 15 doses or until discharge.

Results: The groups were equal with respect to age, gender, indication, surgeon, and type of diversion. Patients who received alvimopan experienced a shorter length of stay (LOS) versus those in who did not receive alvimopan (10.5 vs. 8.6 days, p = 0.005, 95% CI 0.6-3.3). Readmission for ileus was low in both alvimopan and control groups (0% and 4.4%, respectively). Costs were significantly lower in the alvimopan group than the control groups (2012 USD 32,443 vs. 40,604 p <0.001). This difference stood up to multivariate analysis with a $7,062 difference in hospital stay.

Conclusions: Use of alvimopan in the routine perioperative care of our cystectomy and urinary diversion patients has decreased LOS by 1.9 days. Additionally, institution of routine perioperative alvimopan has reduced costs by $7,062 per admission (20% reduction). This demonstrates a real world application of alvimopan at a moderate volume center.

Keywords: alvimopan; bladder cancer; cost–effectiveness; cystectomy; length–of–stay; urinary diversion.

Figures

Figure 1
Figure 1
Quantile LOS.
Figure 2
Figure 2
Cost per hospitalization with and without alvimopan (thousands 2012 USD).

References

    1. Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164–174.
    1. Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA., Jr Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol. 2003;169:101–104.
    1. Hollenbeck BK, Miller DC, Taub D, Dunn RL, Khuri SF, Henderson WG, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol. 2005;174:1231–1237.
    1. Svatek RS, Fisher MB, Williams MB, Matin SF, Kamat AM, Grossman HB, et al. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology. 2010;76:1419–1424.
    1. Lee KL, Freiha F, Presti JC, Jr, Gill HS. Gender differences in radical cystectomy: complications and blood loss. Urology. 2004;63:1095–1099.
    1. Ng CK, Kauffman EC, Lee MM, Otto BJ, Portnoff A, Ehrlich JR, et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol. 2010;57:274–281.
    1. Soulié M, Straub M, Gamé X, Seguin P, De Petriconi R, Plante P, Hautmann RE. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol. 2002;167:1325–1328.
    1. Konety BR, Allareddy V. Influence of post–cystectomy complications on cost and subsequent outcome. J Urol. 2002;177:280–287.
    1. Maffezzini M, Gerbi G, Campodonico F, Parodi D, Capponi G, Spina A, Guerrieri AM. Peri–operative management of ablative and reconstructive surgery for invasive bladder cancer in the elderly. Surg Oncol. 2004;13:197–200.
    1. Inman BA, Harel F, Tiguert R, Lacombe L, Fradet Y. Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients. J Urol. 2003;170:1888–1891.
    1. Shafii M, Murphy DM, Donovan MG, Hickey DP. Is mechanical bowel preparation necessary in patients undergoing cystectomy and urinary diversion? BJU Int. 2002;89:879–881.
    1. Choi H, Kang SH, Yoon DK, Kang SG, Ko HY, Moon du G, et al. Chewing gum has a stimulatory effect on bowel motility in patients after open or robotic radical cystectomy for bladder cancer: a prospective randomized comparative study. Urology. 2011;77:884–890.
    1. Kouba EJ, Wallen EM, Pruthi RS. Gum chewing stimulates bowel motility in patients undergoing radical cystectomy with urinary diversion. Urology. 2007;70:1053–1056.
    1. Pillai P, McEleavy I, Gaughan M, Snowden C, Nesbitt I, Durkan G, et al. A double–blind randomized controlled clinical trial to assess the effect of Doppler optimized intraoperative fluid management on outcome following radical cystectomy. J Urol. 2011;86:2201–2206.
    1. Brodner G, Van Aken H, Hertle L, Fobker M, Von Eckardstein A, Goeters C, et al. Multimodal perioperative management–combining thoracic epidural analgesia, forced mobilization, and oral nutrition–reduces hormonal and metabolic stress and improves convalescence after major urologic surgery. Anesth Analg. 2001;92:1594–1600.
    1. Pruthi RS, Nielsen M, Smith A, Nix J, Schultz H, Wallen EM. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg. 2010;210:93–99.
    1. Liu SS, Hodgson PS, Carpenter RL, Fricke JR., Jr ADL 8–2698, a trans–3,4–dimethyl–4–(3–hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther. 2001;69:66–71.
    1. Ludwig K, Enker WE, Delaney CP, Wolff BG, Du W, Fort JG, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surgery. 2008;143:1098–1105.
    1. Wolff BG, Viscusi ER, Delaney CP, Du W, Techner L. Patterns of gastrointestinal recovery after bowel resection and total abdominal hysterectomy: pooled results from the placebo arms of alvimopan phase II North American clinical trials. J Am Coll Surg. 2007;205:43–51.
    1. Delaney CP, Wolff BG, Viscusi ER, Senagore AJ, Fort JG, Du W, et al. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase II studies. Ann Surg. 2007;245:355–363.
    1. Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, Wallin BA, et al. Alvimopan, a ovel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double–blind, placebo–controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004;240:728–734.
    1. Bell TJ, Poston SA, Kraft MD, Senagore AJ, Delaney CP, Techner L. Economic analysis of alvimopan in North Anerican Phase III efficacy trials. Am J Health Syst Pharm. 2009;66:1362–1368.
    1. Poston S, Broder MS, Gibbons MM, Maclaren R, Chang E, Vandepol CJ, et al. Impact of alvimopan (entereg) on hospital costs after bowel resection: results from a large inpatient database. P&T. 2011;36:209–220.
    1. Vora AA, Harbin A, Rayson R, Christiansen K, Ghasemian R, Hwang J, et al. Alvimopan provides rapid gastrointestinal recovery without nasogastric tube decompression after radical cystectomy and urinary diversion. Can J Urol. 2012;19:6293–6298.
    1. US Bureau of Labor Statistics. Consumer Price Index. Available at: . Accessed: March 5, 2013.
    1. Ramirez JA, McIntosh AG, Strehlow R, Lawrence VA, Parekh DJ, Svatek RS. Definition, incidence, risk factors, and prevention of paralytic ileus following radical cystectomy: A systematic review. Eur Urol. 2013;64:588–597.
    1. Jacobs BL, Zhang Y, Tan HJ, Ye Z, Skolarus TA, Hollenbeck BK. Hospitalization trends after prostate and bladder surgery: implications of potential payment reforms. J Urol. 2013;189:59–65.
    1. Yu HY, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Nguyen PL, Choueiri TK, et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot–assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012;61:1239–1244.
    1. Webster L, Jansen JP, Peppin J, Lasko B, Irving G, et al. Alvimopan, a peripherally acting mu–opioid receptor (PAM–OR) antagonist for the treatment of opioid–induced bowel dysfunction: results from a randomized, double–blind, placebo–controlled, dose–finding study in subjects taking opioids for chronic non–cancer pain. Pain. 2008;137:428–440.
    1. Hilton WM, Lotan Y, Parekh DJ, Basler JW, Svatek RS. Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost–effectiveness analysis. BJU Int. 2012;111:1054–1060.
    1. Lee CT, Chang SS, Kamat AM, et al. Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo–Controlled Trial. Eur Urol. 2014;14:S0302–28380.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться